Proton-Pump Inhibitor (No. II)

The Proton-Pump Inhibitor No. II docket, with 11,404 actions coordinated in the District of New Jersey, is one of the larger active drug dockets in the current federal MDL system. Claims allege that long-term use of proton-pump inhibitor heartburn medications, a widely prescribed drug class, causes chronic kidney injury, including acute kidney injury progressing to chronic kidney disease in some claimants.

That scale supports genuine portfolio-level financing activity, but the underlying causation theory here is worth underwriting carefully: proton-pump inhibitors are used by a very large population for a common condition, and kidney disease has many potential causes independent of medication use, including diabetes, hypertension, and age-related decline. That means specific-causation evidence, meaning a claimant's use duration and dosage, kidney-function testing over time, and the presence or absence of competing risk factors, carries significant weight in how an individual claim's strength should be assessed, more so than in a docket with a more mechanically distinct injury signature.

Medical-lien exposure is meaningful given that chronic kidney disease, particularly if it progresses toward dialysis or transplant, involves substantial and often long-term treatment costs. For a firm with a large PPI claim inventory, portfolio finance is a natural structure given the docket's scale, though underwriting should still weight claim-level differentiation given how contested specific causation can be for any individual claimant with competing risk factors. Funders should also expect summary-judgment activity around causation to be a more prominent feature of this docket's near-term calendar than bellwether trial scheduling alone, given how central individualized causation proof is to this claim type.

Criterica Capital's mass tort finance product applies here. A structural read on this docket's general-causation and summary-judgment posture, which matters more in a docket like this than in many device dockets, is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.